ReviewNature reviews. Gastroenterology & hepatology2019
Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD.
Review in Nature reviews. Gastroenterology & hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 467 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
467 citing papers in PubMed, 2 syntheses or guidelines pooled it, 854 citations in OpenAlex.
- Gut microbiota and ulcerative colitis: a bibliometric analysis of knowledge structure, research hotspots, and future directions.Frontiers in microbiology · 2026Pooled it
- The Impact ofCurrent neuropharmacology · 2025Pooled it
- Modification of the dextran sodium sulfate model to identify agents that induce or exacerbate inflammatory bowel disease.Journal of immunotoxicology · 2026Article
- Blocking the mCellular & molecular immunology · 2026Article
- Engineered microvesicle-mediated multimodal therapy resolves ulcerative colitis via synergistic immunoregulation, barrier restoration, and microbiota remodeling.Materials today. Bio · 2026Article
- Compound Kushen Injection Alleviates Experimental Colitis in Mice by Regulating Macrophage Polarization through TLR4/NF-κB Signaling.Chinese journal of integrative medicine · 2026Article
- Regulation of Inducible Nitric Oxide Synthase (NOS2) Expression in Healthy and Inflamed Bowel: A Narrative Review.International journal of molecular sciences · 2026Review
- Vitamin D and Intestinal Diseases: Impact on Intestinal Immunity and Gut Barrier Function.Diseases (Basel, Switzerland) · 2026Review
- Engineering of Artificial Antioxidase Enables Boosted Catalytic Activity in Inflammatory Bowel Disease Alleviation.Angewandte Chemie (International ed. in English) · 2026Article
- Review
- GPR15-guided CD8Nature · 2026Article
- Orally administered biomimetic nanovesicles engineered with FGF2 orchestrate mucosal healing and microbiome remodeling in inflammatory bowel disease.Materials today. Bio · 2026Article
- Monocyte Distribution Width Differentiates Bacterial Enterocolitis from Acute Severe Ulcerative Colitis in the Emergency Department.Digestive diseases and sciences · 2026Article
- Mucin armoured diethylaminoethyl-dextran cloaked rebamipide based oral nanoformulation for the therapy of inflammatory bowel disease.Materials today. Bio · 2026Article
- Tissue-resident colon macrophages shape the microbiome and regulate mucosal healing via ferroportin.Cell reports · 2026Article
- Unraveling Effects and Pharmacological Mechanisms of Phellodendrine on Inflammatory Bowel Disease.Biomolecules · 2026Article
- TheCells · 2026Article
- cGAS/STING Signaling in Ulcerative Colitis: Mechanism and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Glycocholic acid inhibits TRIB3-ID1 axis to acelerate colitis progression via suppressing intestinal stem cell renewal.Nature communications · 2026Article
- Macrophage USP9X attenuates colitis by restricting oncostatin M production via K27-linked deubiquitination of STAT1.Cellular & molecular immunology · 2026Article
407 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophages are the gatekeepers of intestinal immune homeostasis as they discriminate between innocuous antigens and potential pathogens to maintain oral tolerance. However, in individuals with a genetic and environmental predisposition, regulation of intestinal immunity is impaired, leading to chronic relapsing immune activation and pathologies of the gastrointestinal tract, such as IBD. As evidence suggests a causal link between defects in the resolution of intestinal inflammation and altered monocyte-macrophage differentiation in patients with IBD, macrophages have been considered as a novel potential target to develop new treatment approaches. This Review discusses the molecular and cellular mechanisms involved in the differentiation and function of intestinal macrophages in homeostasis and inflammation, and their role in resolving the inflammatory process. Understanding the molecular pathways involved in the specification of intestinal macrophages might lead to a new class of targets that promote remission in patients with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.